New study tracks kidney health in myeloma patients on daratumumab
NCT ID NCT06549634
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study measured certain proteins in the blood and urine of 20 newly diagnosed multiple myeloma patients before and 30 days after starting daratumumab. The goal was to see if these markers could help detect early kidney injury. Participants provided samples during routine lab visits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which emergency dialysis saves more lives? a new study investigates
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple sensor on the back could warn of kidney danger during heart surgery